Page 1

November 15 , 2021 E dermata Dermata Therapeutics , Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Announced positive topline results from DMT310 proof of concept ( POC ) study in mild - to - moderate psoriasis - - Closed upsized $ 18.0 million initial public offering ( IPO ) on Nasdaq Capital Market - - Topline results from DMT410 POC study in multiple aesthetic skin conditions to be presented November 19 , 2021 - - On track to initiate DMT310 Phase 2 study for moderate - to - severe rosacea in Q4 2021- SAN DIEGO , CA / ACCESSWIRE / November 15 , 2021 / Dermata Therapeutics , Inc. ( NASDAQ : DRMA ) ( NASDAQ : DRMAW ) ( " Dermata " or the " Company " ) , a clinical - stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions , today reported financial results for the third quarter ended September 30 , 2021 and highlighted recent corporate progress . " The third quarter of 2021 was transformational for Dermata , as we completed our IPO , bolstered our executive team and Board of Directors , and continued to progress our clinical pipeline in multiple indications , " commented Gerry Proehl , Dermata's Chairman , President and Chief Executive Officer . " In October , we announced positive topline results from our Phase 1b proof of concept clinical trial of our lead candidate DMT310 for the treatment of mild - to - moderate psoriasis . Based upon the improvements witnessed across all three of our exploratory endpoints , combined with the safety and tolerability profile observed , we plan to continue investigation of DMT310 in psoriasis . Moving forward , we are excited to build on our momentum and present topline results from our Phase 1b proof of concept study of DMT410 in multiple aesthetic skin conditions and to start enrolling our Phase 2 trial of DMT310 in moderate - to - severe rosacea , " concluded Mr. Proehl . Corporate Highlights • Announced Positive Topline Results from Phase 1b POC Clinical Trial of DMT310 in Mild - to - moderate Psoriasis . On October 18 , 2021 , Dermata announced results from its DMT310 product candidate's once - weekly use in mild - to - moderate psoriasis patients . DMT310 demonstrated efficacy improvements in PGA , PASI and pruritus scores for the target lesions as well as an acceptable safety and tolerability profile . DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6 % of patients , a total PASI score of 0 or 1 for the target lesion in 25.9 % of patients , and a 19.6 % reduction from baseline in pruritus at week 8 . ⚫ Closed Upsized $ 18.0 Million Initial Public Offering on Nasdaq Capital Market . In